JP2020523351A5 - - Google Patents

Download PDF

Info

Publication number
JP2020523351A5
JP2020523351A5 JP2019568599A JP2019568599A JP2020523351A5 JP 2020523351 A5 JP2020523351 A5 JP 2020523351A5 JP 2019568599 A JP2019568599 A JP 2019568599A JP 2019568599 A JP2019568599 A JP 2019568599A JP 2020523351 A5 JP2020523351 A5 JP 2020523351A5
Authority
JP
Japan
Prior art keywords
alkyl
formula
heterocycloalkyl
cycloalkyl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019568599A
Other languages
English (en)
Japanese (ja)
Other versions
JP7257338B2 (ja
JP2020523351A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/037503 external-priority patent/WO2018232094A1/en
Publication of JP2020523351A publication Critical patent/JP2020523351A/ja
Publication of JP2020523351A5 publication Critical patent/JP2020523351A5/ja
Priority to JP2023060086A priority Critical patent/JP7636460B2/ja
Application granted granted Critical
Publication of JP7257338B2 publication Critical patent/JP7257338B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019568599A 2017-06-15 2018-06-14 Alk2キナーゼのイミダゾール含有阻害剤 Active JP7257338B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023060086A JP7636460B2 (ja) 2017-06-15 2023-04-03 Alk2キナーゼのイミダゾール含有阻害剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762520150P 2017-06-15 2017-06-15
US62/520,150 2017-06-15
PCT/US2018/037503 WO2018232094A1 (en) 2017-06-15 2018-06-14 Imidazole-containing inhibitors of alk2 kinase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023060086A Division JP7636460B2 (ja) 2017-06-15 2023-04-03 Alk2キナーゼのイミダゾール含有阻害剤

Publications (3)

Publication Number Publication Date
JP2020523351A JP2020523351A (ja) 2020-08-06
JP2020523351A5 true JP2020523351A5 (cg-RX-API-DMAC7.html) 2021-07-26
JP7257338B2 JP7257338B2 (ja) 2023-04-13

Family

ID=64659499

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019568599A Active JP7257338B2 (ja) 2017-06-15 2018-06-14 Alk2キナーゼのイミダゾール含有阻害剤
JP2023060086A Active JP7636460B2 (ja) 2017-06-15 2023-04-03 Alk2キナーゼのイミダゾール含有阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023060086A Active JP7636460B2 (ja) 2017-06-15 2023-04-03 Alk2キナーゼのイミダゾール含有阻害剤

Country Status (20)

Country Link
US (3) US11661426B2 (cg-RX-API-DMAC7.html)
EP (1) EP3638229A4 (cg-RX-API-DMAC7.html)
JP (2) JP7257338B2 (cg-RX-API-DMAC7.html)
KR (2) KR20240063970A (cg-RX-API-DMAC7.html)
CN (2) CN110913855B (cg-RX-API-DMAC7.html)
AR (1) AR112027A1 (cg-RX-API-DMAC7.html)
AU (2) AU2018283053C1 (cg-RX-API-DMAC7.html)
BR (1) BR112019026517A2 (cg-RX-API-DMAC7.html)
CA (1) CA3066164A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019003669A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020000194A2 (cg-RX-API-DMAC7.html)
EA (1) EA202090052A1 (cg-RX-API-DMAC7.html)
IL (2) IL271109B2 (cg-RX-API-DMAC7.html)
MA (1) MA49401A (cg-RX-API-DMAC7.html)
MX (2) MX2019015226A (cg-RX-API-DMAC7.html)
MY (1) MY204609A (cg-RX-API-DMAC7.html)
PH (1) PH12019502781A1 (cg-RX-API-DMAC7.html)
SG (1) SG10202112496SA (cg-RX-API-DMAC7.html)
TW (2) TWI833696B (cg-RX-API-DMAC7.html)
WO (1) WO2018232094A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2970205T (pt) 2013-03-14 2019-08-26 Tolero Pharmaceuticals Inc Inibidores da jak2 e da alk2 e métodos para a sua utilização
AR112027A1 (es) 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
KR20210038906A (ko) 2018-07-26 2021-04-08 스미토모 다이니폰 파마 온콜로지, 인크. 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
WO2020068729A1 (en) * 2018-09-25 2020-04-02 Incyte Corporation Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators
CA3117695A1 (en) 2018-10-26 2020-04-30 Keros Therapeutics, Inc. Crystal forms of an alk2 inhibitor
WO2020156445A1 (zh) 2019-01-29 2020-08-06 山东轩竹医药科技有限公司 己酮糖激酶抑制剂及其用途
WO2020235902A1 (ko) * 2019-05-17 2020-11-26 주식회사 보로노이 헤테로고리 융합 피리미딘 유도체 및 이의 용도
MX2021014273A (es) * 2019-05-21 2022-01-06 Voronoi Inc Derivado de heteroarilo que contiene n y composicion farmaceutica que lo comprende como principio activo para la prevencion o el tratamiento de cancer.
MX2022001741A (es) * 2019-08-13 2022-03-11 Blueprint Medicines Corp Sal y formas cristalinas de un inhibidor de la cinasa similar a un receptor de activina.
US12486274B2 (en) 2020-01-13 2025-12-02 Verge Analytics, Inc. Substituted pyrazolo-pyrimidines and uses thereof
WO2021183439A1 (en) * 2020-03-09 2021-09-16 Verge Analytics, Inc. Substituted furo[3,2-d]pyrimidines and uses thereof
GB202006382D0 (en) 2020-04-30 2020-06-17 Spermatech As Use
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
AU2021409381A1 (en) * 2020-12-21 2023-08-03 Biocryst Pharmaceuticals, Inc. Dosing regimens for oral alk2 kinase inhibitors
GEAP202416425A (en) * 2021-05-25 2024-02-12 Biocryst Pharm Inc Imidazole-containing inhibitors of alk2 kinase
TW202329937A (zh) 2021-12-03 2023-08-01 美商英塞特公司 雙環胺ck12抑制劑
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
EP4504341A1 (en) 2022-04-08 2025-02-12 Shy Therapeutics LLC Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
WO2023198114A1 (zh) * 2022-04-13 2023-10-19 杭州邦顺制药有限公司 Alk2激酶抑制剂
WO2025240752A1 (en) * 2024-05-15 2025-11-20 University Of Miami Mmp-13 antagonists

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
LU86084A1 (fr) 1985-09-20 1987-04-02 Faco Sa Apparei de massage electrique
US5102417A (en) 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO1990013332A1 (en) 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Stent with sustained drug delivery
EP0470246B1 (en) 1990-02-28 1995-06-28 Medtronic, Inc. Intralumenal drug eluting prosthesis
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US5419760A (en) 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US6335324B1 (en) 1998-06-25 2002-01-01 Bristol-Myers Squibb Co. Beta lactam compounds and their use as inhibitors of tryptase
CA2386955A1 (en) * 1999-11-22 2001-05-31 Warner-Lambert Company Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
BR0111754A (pt) 2000-06-28 2003-04-29 Astrazeneca Ab Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica
AU2001290912A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2003022214A2 (en) 2001-09-06 2003-03-20 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
US6846928B2 (en) 2002-03-15 2005-01-25 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US6770729B2 (en) 2002-09-30 2004-08-03 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
WO2004081000A1 (en) 2003-03-10 2004-09-23 Astrazeneca Ab Quinazoline derivatives
MY145634A (en) 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
US20070244114A1 (en) 2004-07-06 2007-10-18 Myriad Genetics, Incorporated Compounds and therapeutical use thereof
JP2008525422A (ja) 2004-12-23 2008-07-17 ファイザー・プロダクツ・インク 抗癌剤として有用な複素芳香族誘導体
US7572809B2 (en) 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
SI2041138T1 (sl) * 2006-07-07 2014-08-29 Bristol-Myers Squibb Company Pirolotriazin kinazni inhibitorji
US7531539B2 (en) 2006-08-09 2009-05-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2009084695A1 (ja) 2007-12-28 2009-07-09 Carna Biosciences Inc. 2-アミノキナゾリン誘導体
JP2012504157A (ja) 2008-09-30 2012-02-16 アストラゼネカ アクチボラグ 複素環式jakキナーゼ阻害剤
CN102625804B (zh) * 2009-06-12 2015-04-08 Abivax公司 用于治疗aids的化合物
AR079814A1 (es) * 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
US8470820B2 (en) 2010-01-22 2013-06-25 Hoffman-La Roche Inc. Nitrogen-containing heteroaryl derivatives
JP6121658B2 (ja) 2011-06-29 2017-04-26 大塚製薬株式会社 治療用化合物、及び関連する使用の方法
US9422267B2 (en) 2012-12-26 2016-08-23 Medivation Technologies, Inc. Fused pyrimidine compounds and use thereof
PT2970205T (pt) * 2013-03-14 2019-08-26 Tolero Pharmaceuticals Inc Inibidores da jak2 e da alk2 e métodos para a sua utilização
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
CN108239071B (zh) 2016-12-27 2020-12-04 沈阳药科大学 酰胺及硫代酰胺类衍生物及其制备方法和应用
AR112027A1 (es) 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol

Similar Documents

Publication Publication Date Title
JP2023551174A5 (cg-RX-API-DMAC7.html)
JP2013538235A5 (cg-RX-API-DMAC7.html)
JP2022512482A5 (cg-RX-API-DMAC7.html)
JP2019034943A5 (cg-RX-API-DMAC7.html)
JP2016121196A5 (cg-RX-API-DMAC7.html)
JP2017526677A5 (cg-RX-API-DMAC7.html)
JP2008525416A5 (cg-RX-API-DMAC7.html)
JP2019522055A5 (cg-RX-API-DMAC7.html)
JP2014521688A5 (cg-RX-API-DMAC7.html)
JP2016505586A5 (cg-RX-API-DMAC7.html)
JP2022108241A5 (cg-RX-API-DMAC7.html)
JP2005514420A5 (cg-RX-API-DMAC7.html)
JP2018536648A5 (cg-RX-API-DMAC7.html)
JP2009519243A5 (cg-RX-API-DMAC7.html)
JP2010031025A5 (cg-RX-API-DMAC7.html)
JP2007511504A5 (cg-RX-API-DMAC7.html)
JP2014500265A5 (cg-RX-API-DMAC7.html)
JP2010527913A5 (cg-RX-API-DMAC7.html)
JP2019500387A5 (cg-RX-API-DMAC7.html)
JP2007519721A5 (cg-RX-API-DMAC7.html)
JP2009536221A5 (cg-RX-API-DMAC7.html)
JP2015511232A5 (cg-RX-API-DMAC7.html)
JP2020111571A5 (cg-RX-API-DMAC7.html)
JP2025502748A5 (cg-RX-API-DMAC7.html)
JP2020535124A5 (cg-RX-API-DMAC7.html)